From Medscape Gastroenterology

Medscape Medical News from

Digestive Disease Week (DDW) 2014

May 3 - 6, 2014; Chicago, Illinois

This coverage is not sanctioned by, nor a part of, Digestive Disease Week.

The Wrap-Up

 
 

Trial Slides

  • PEARL-III and PEARL-IV PEARL-III and PEARL-IV Two phase 3, randomized trials find that 12 weeks of ABT-450/r-ombitasvir and dasabuvir with or without ribavirin is effective in patients with chronic HCV genotype 1 infection and no cirrhosis.
 
 

Conference News

Expert Commentary

Pre-Meeting Expert Commentary

Previous Coverage

 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.